Related by context. All words. (Click for frequent words.) 71 tumor progression 68 tumor recurrence 66 metastatic disease 66 virologic failure 66 PSADT 65 imatinib therapy 65 neurologic progression 63 tumor shrinkage 63 sunitinib 63 microalbuminuria 62 progression TTP 62 imatinib 62 metastatic prostate cancer 62 cardiotoxicity 62 androgen deprivation 62 antiviral therapy 62 liver fibrosis 62 bone metastasis 62 virological failure 62 liver metastases 61 distant metastasis 61 abiraterone 61 CMV disease 61 chemoradiotherapy 61 dasatinib 61 viral load 61 biochemical recurrence 61 erlotinib 61 bortezomib 61 cabazitaxel 61 cognitive decline 61 prostate cancer CaP 61 bone metastases 61 HAART 61 progression 61 HNSCC 61 bevacizumab 60 telomere shortening 60 etanercept 60 IGF 1R 60 sustained virologic response 60 NSCLC 60 Hydroxyurea 60 virological response 60 virologic response 60 HCV infected 60 urate levels 60 trastuzumab 60 lung metastasis 60 tamoxifen therapy 60 metastatic renal cell carcinoma 60 topotecan 60 adalimumab 60 heavily pretreated 60 DMARD 60 zoledronic acid 60 PCa 59 bone resorption 59 CMV infection 59 prolongs survival 59 vandetanib 59 HER2 positive breast cancer 59 breast cancer recurrence 59 fibrosis 59 metastatic RCC 59 decitabine 59 tumor regression 59 temsirolimus 59 renal flares 59 hepatic fibrosis 59 T2DM 59 mitoxantrone 59 peginterferon 59 axitinib 59 leukemia AML 59 sustained virological response 59 renal function 59 mRCC 59 SUTENT 59 malignancies 59 proliferative diabetic retinopathy 59 colorectal tumors 59 recurrent VTE 59 brain metastases 59 atherosclerotic disease 59 mycophenolate mofetil 59 median PFS 59 AGILECT R 59 anti TNF 58 gefitinib Iressa 58 fulvestrant 58 plasma uric acid 58 viral loads 58 serum phosphate 58 acute myelogenous leukemia AML 58 interferon therapy 58 cisplatin chemotherapy 58 pCR 58 HCV infection 58 clusterin 58 posaconazole 58 infliximab 58 overt nephropathy 58 transgene expression 58 metformin 58 lupus nephritis 58 APTIVUS r 58 antiretroviral therapy 58 neoadjuvant chemotherapy 58 complete cytogenetic response 58 HCV RNA 58 antiplatelet therapy 58 HIV HCV coinfected 58 erlotinib Tarceva 58 metastases 58 pharmacologic intervention 58 rituximab 58 colorectal cancer 58 mammary tumors 58 antihypertensive therapy 58 NNRTI resistance 58 tumors 58 castration resistant prostate cancer 58 hepatocellular carcinoma 58 imatinib Gleevec 58 brain shrinkage 58 HbA1c levels 58 distant metastases 58 Telintra 58 beta blocker therapy 58 chlorambucil 58 HBV infection 58 sorafenib 58 radiographic progression 58 interferon alpha 58 docetaxel 58 hepatotoxicity 58 DFMO 58 adjuvant therapy 58 pomalidomide 57 immunosuppression 57 metastatic cancer 57 diabetic nephropathy 57 atherosclerosis 57 teriflunomide 57 thrombotic events 57 cognitive impairment 57 glycated hemoglobin levels 57 Bcl xL 57 prostate cancer CRPC 57 DMARDs 57 FOLFOX 57 blastic phase 57 Imatinib 57 gefitinib 57 glufosfamide 57 disease modifying 57 advanced adenomas 57 viral replication 57 antiretroviral naive 57 biochemical relapse 57 CaP 57 tumor regrowth 57 SHPT 57 monotherapy 57 relapsing MS 57 viral suppression 57 HSCT 57 tocilizumab 57 ipsilateral stroke 57 EGFR inhibitors 57 reinfarction 57 kidney function 57 Median survival 57 pegylated liposomal doxorubicin 57 serum calcium levels 57 bronchopulmonary dysplasia 57 gemcitabine 57 FOLFOX4 57 anti leukemic 57 carotid IMT 57 KRAS mutant tumors 57 azacitidine 57 BRAF mutation 57 cART 57 calcitriol 57 nephropathy 57 mg kg dose 57 relapsed AML 57 Kaplan Meier estimate 57 leukemia ALL 57 gout flares 57 DAPT 57 non squamous NSCLC 57 CD4 counts 57 proteinuria 57 differentiated thyroid 57 antiangiogenic therapy 57 bosentan 57 HCV 57 preoperative chemotherapy 57 prospectively defined 57 lung fibrosis 57 timepoints 57 colorectal adenomas 57 5-FU/LV 57 trastuzumab Herceptin ® 57 evaluable patients 57 ancrod 57 posttransplant 57 clodronate 56 statin therapy 56 TNFα 56 lamivudine 56 immune reconstitution 56 renal toxicity 56 CLL 56 cardiovascular mortality 56 docetaxel chemotherapy 56 metastatic lung cancer 56 pancreatic adenocarcinoma 56 antithrombotic therapy 56 pertuzumab 56 advanced adenoma 56 genotypic resistance 56 EGFR TKI 56 NNRTIs 56 hormone refractory 56 TACE 56 hypercalcemia 56 heavily pretreated patients 56 interferon 56 diabetic kidney 56 EBRT 56 Sustained Virological Response 56 CD4 cell 56 colorectal carcinoma 56 EGFR mutations 56 severe neutropenia 56 LV dysfunction 56 cellular senescence 56 idarubicin 56 LY# [003] 56 malignant transformation 56 IGFBP 56 variceal bleeding 56 adalimumab Humira 56 Median progression 56 telomerase activity 56 cardiac toxicity 56 telomere length 56 TRIOLEX 56 inhibitor RG# 56 androgen therapy 56 interferon alfa 56 PEGylated interferon beta 1a 56 virologic 56 thromboembolic events 56 talabostat 56 relapsed ovarian cancer 56 clinically localized prostate 56 macroalbuminuria 56 tumor regressions 56 interferon ribavirin 56 paricalcitol 56 surrogate endpoint 56 cataract formation 56 Dasatinib 56 MS relapses 56 rindopepimut 56 imetelstat 56 HER2 overexpression 56 VT VF 56 octreotide LAR 56 clinically meaningful improvements 56 microvascular complications 56 fenretinide 56 Natalizumab 56 cerebral vasospasm 56 Myelodysplastic Syndrome MDS 56 metastatic malignant 56 clinically meaningful 56 HbF 56 mg/m2 dose 56 presymptomatic 56 letrozole 56 liver histology 56 cystatin C 56 tyrosine kinase inhibitors 56 nitazoxanide 56 interferon beta 56 serum calcium 56 free survival PFS 56 corrected QT interval 56 antidepressant therapy 56 cachexia 56 FOLFIRI 56 T1DM 56 telomere lengths 56 stage IIIB 56 adenoma recurrence 56 QTc interval 56 prednisone prednisolone 56 glycosylated hemoglobin HbA1c 56 TGF β 56 EGFR mutation 56 HBeAg negative 56 nilotinib 56 anti VEGF 56 diabetic retinopathy DR 56 peginterferon alfa 2a 56 RRMS patients 56 CCyR 56 tafamidis 56 viral kinetics 56 basal cell carcinoma BCC 56 lung tumors 56 serum urate levels 55 exacerbations 55 prostate tumor 55 fondaparinux 55 brain atrophy 55 abiraterone acetate 55 postoperative AF 55 fibrotic disease 55 dasatinib Sprycel 55 EBV infection 55 GVHD 55 NRTIs 55 HER2 positive metastatic breast 55 prior chemotherapy regimens 55 osteopontin 55 sorafenib Nexavar 55 seropositive patients 55 IV NSCLC 55 hyperphosphatemia 55 androgen ablation 55 IFN beta 55 Doxil ® 55 temozolomide 55 neuronal dysfunction 55 mapatumumab 55 motor neuron degeneration 55 β blockers 55 tumor progression TTP 55 osteoclast activity 55 androgen suppression 55 serum testosterone 55 glucocorticoid 55 virologic responses 55 nucleoside analogues 55 recurrent glioblastoma multiforme 55 relapsed SCLC 55 evaluable 55 losartan 55 rhGH 55 renal dysfunction 55 OADs 55 HIV infection 55 platelet reactivity 55 chronic lymphocytic leukemia CLL 55 myocardial ischemia 55 tiotropium 55 lymphocyte counts 55 metastatic malignant melanoma 55 methotrexate therapy 55 adefovir 55 induce apoptosis 55 gastrointestinal stromal tumor GIST 55 HGS ETR1 55 tamoxifen 55 GnRH agonist 55 chronic HCV infection 55 liver metastasis 55 relapsed MM 55 TNF inhibitor 55 cisplatin 55 rapid virologic response 55 CD4 + cell 55 breast cancer metastasis 55 COPD exacerbations 55 COPAXONE R 55 IFN gamma 55 complete cytogenetic 55 HAART regimens 55 Laquinimod 55 complete remissions 55 vicriviroc 55 mitochondrial function 55 Torisel 55 ZD# [001] 55 relapsing remitting multiple sclerosis 55 mutated KRAS 55 Kaplan Meier analysis 55 neoadjuvant therapy 55 beta interferon 55 nonadherence 55 symptom onset 55 ruboxistaurin 55 Symadex 55 VEGF inhibitors 55 aromatase inhibitor 55 platelet aggregation 55 recurrent GBM 55 metastatic gastric 55 perioperative complications 55 antitumor effect 55 TNFa 55 relapse 55 antiangiogenic 55 enzymatic activity 55 undetectable HCV RNA 55 platelet function 55 lymph node metastasis 55 diabetic retinopathy 55 timepoint 55 HIV RNA 55 KRAS mutation 55 IFN γ 55 cetuximab 55 metastasis 55 premalignant 55 spontaneous preterm delivery 55 Xeloda 55 pulmonary exacerbations 55 advanced NSCLC 55 PAOD 55 rapamycin 55 cervical lesions 55 cangrelor 55 pyridostigmine 55 rtPA 55 natalizumab 55 nonmelanoma skin cancers 55 metastatic kidney 55 hormonal therapy 55 CD8 responses 55 cytotoxic therapy 55 fibrosis progression 55 methotrexate monotherapy 55 TNF antagonist 55 Hepatocellular Carcinoma HCC 55 nonresponders 55 K ras mutations 55 cardiovascular morbidity 55 SUVmax 55 adjuvant chemotherapy 55 QTc prolongation 55 PREZISTA r 55 IFN alpha 55 T2D 55 recurrent venous thromboembolism 55 CR nPR 55 de ath 55 cystectomy 55 lapatinib Tykerb 55 NAFLD 55 nephrotoxicity 54 hour bronchodilation 54 carboplatin paclitaxel 54 endothelial dysfunction 54 ataluren 54 anastrozole 54 alteplase 54 RAPAFLO R 54 Dose escalation 54 anthracycline taxane 54 nonfatal MI 54 CIMZIA ™ 54 Notch1 54 HGS# 54 HCV replication 54 antioxidant supplementation 54 CA4P 54 TNF inhibitors 54 primary endpoint 54 PGE2 54 RSV infection 54 INCB# [001] 54 durable remissions 54 aromatase inhibitor therapy 54 nucleotide analog 54 immunosuppressive regimens 54 albuminuria 54 specific antigen PSA 54 metastatic breast cancer 54 glycemia 54 neurocognitive deficits 54 LVEF 54 mitochondrial toxicity 54 selenium supplementation 54 locoregional 54 Parkinson disease PD 54 KRAS mutations 54 plasma viremia 54 sporadic ALS 54 sirolimus 54 uric acid lowering 54 diabetic gastroparesis 54 neoadjuvant treatment 54 prognostic indicators 54 IFN α 54 seroconversion 54 platelet activation 54 mTOR inhibitors 54 prostate cancer metastases 54 antifungal therapy 54 antidiabetic therapy 54 secondary hyperparathyroidism 54 colorectal adenoma 54 SERCA2a 54 chlamydial infection 54 growth hormone secretion 54 pegylated interferon 54 A1c levels 54 MGUS 54 corticosteroid therapy 54 plasma kallikrein 54 hedgehog pathway 54 chemotherapeutic agent 54 subclinical hypothyroidism 54 insulin glargine 54 baseline HbA1c 54 CLL cells 54 proliferative retinopathy 54 PSN# [002] 54 HAART regimen 54 visilizumab 54 treatment regimens 54 rheumatoid arthritis RA 54 carvedilol 54 G CSF 54 relapsed ALL 54 anakinra 54 STRIDE PD 54 prostate cancer PCa 54 IL 1ß 54 ibandronate 54 Clusterin 54 serum PSA 54 PNH patients 54 Garcia Manero 54 antiestrogen 54 mammographic density 54 secondary endpoint 54 pharmacologic 54 poorer prognosis 54 coronary artery disease 54 levodopa therapy 54 Hb A1C 54 cediranib 54 prognostic indicator 54 candesartan 54 NNRTI 54 lactate dehydrogenase 54 nucleoside analog 54 ximelagatran 54 hyperbilirubinemia 54 daclizumab 54 placebo 54 methotrexate 54 familial ALS 54 paroxysmal AF 54 carcinoid tumors 54 mucosal healing 54 anticoagulation 54 efalizumab 54 TNF α 54 prespecified 54 baminercept 54 olaparib 54 annualized relapse 54 antithrombotic 54 WT1 54 cilengitide 54 intermittent dosing 54 VZV 54 Campath alemtuzumab 54 QTc intervals 54 cardiovascular disease 54 R0 resection 54 platelet inhibition 54 nonsense mutation 54 ribavirin RBV 54 pathologic 54 exemestane 54 tofacitinib 54 choroidal vasculopathy 54 metastatic tumors 54 GVAX 54 hypercholesterolemia 54 pazopanib 54 neutrophil counts 54 cancer cachexia 54 Hsp# inhibition 54 immunomodulatory therapy 54 goserelin 54 neurocognitive function 54 estramustine 54 prostate tumors 54 S#A# [002] 54 EXJADE 54 refractory CTCL 54 nab paclitaxel 54 GIST tumors 54 lactate dehydrogenase LDH 54 GvHD 54 TDF FTC 54 neoplasia 54 lung function 54 ispinesib administered 54 VEGF receptor 54 recurrent prostate cancer 54 colorectal liver metastases 54 idraparinux 54 stratifying patients 54 Akt activation 54 response CCyR 54 levodopa 54 grade gliomas 54 neurodevelopmental impairment 54 taxane therapy 54 tanespimycin 54 plasma glucose 54 reach statistical significance 54 juvenile idiopathic arthritis 54 insulin sensitizing 54 gemcitabine carboplatin 54 tumor histology 54 anthracycline containing 54 metastatic melanoma 54 endometrial hyperplasia 54 glycosylated hemoglobin levels 54 TTR amyloidosis 54 cerebrovascular events 54 oblimersen 54 glucocorticoids 54 disease progression TTP 54 intensive statin therapy 54 atheroma volume 54 disease modifying antirheumatic 54 androgen independent 54 plus dexamethasone 54 GBA mutations 54 FOLFIRINOX 54 myocardial infarction 54 prostate carcinogenesis 54 panobinostat 54 pancreatic carcinoma 54 therapeutic regimens 54 hsCRP levels 54 inflammatory biomarkers 54 plasma glucose levels 54 initiating HAART 54 teriparatide 54 p# activation 54 XELOX 54 serum HBV DNA 54 serum phosphate levels 54 eGFR 54 decompensated cirrhosis 54 cetuximab Erbitux 54 malignant pleural mesothelioma 54 glioblastoma 54 PASI scores 54 riociguat 54 elotuzumab 54 defibrotide 54 toxicities 54 B7 H3 54 Xelox 54 antiretroviral therapy ART 54 serum phosphorus 54 multiple myeloma 54 adjuvant therapies 54 smoldering multiple myeloma 54 achieved sustained virological 54 cytogenetic response 54 lipid lowering therapies 54 plasma renin activity 54 raltegravir 54 histone deacetylases 54 Gleevec 54 corticosteroid dose 54 pancreatic neuroendocrine tumors 54 hemoglobin A1c levels 54 cardiovascular hospitalization 54 ribavirin therapy 54 schizophrenia CIAS 54 ischemic 54 virologically 54 lymphocyte count 54 reperfusion injury 54 elevated triglyceride levels 54 CMV infections 54 superficial bladder cancer 54 clinically meaningful improvement 54 bezafibrate 54 cinacalcet 54 olmesartan 54 urothelial bladder cancer 54 ATACAND 54 cyclin E 54 locoregional recurrence 54 nonvertebral fractures 54 Bevacizumab 54 gastric carcinoma 54 GAMMAGARD 54 TNF alpha 54 IRX 2 54 clopidogrel 54 HbA1C 54 antiviral efficacy 54 clinically relevant 54 restenosis 53 ErbB2 positive 53 POAG 53 Bezielle 53 angiogenesis inhibitor 53 romiplostim 53 autoantibodies 53 figitumumab 53 GBM tumors 53 leukocyte count 53 EGFr 53 HBeAg positive patients 53 oral FTY# 53 MMP inhibitors 53 alanine aminotransferase ALT 53 co morbidities 53 BRAF inhibitor 53 Subgroup analysis 53 5FU 53 irinotecan chemotherapy 53 dexpramipexole 53 nerve degeneration 53 CAG repeats 53 Prognostic factors 53 panitumumab Vectibix 53 immunosuppressant therapy 53 activin 53 SHBG levels 53 natriuretic peptide 53 ischemic stroke 53 refractory gout 53 hippocampal atrophy 53 metastatic 53 BH4 53 bevacizumab Avastin 53 amyloid deposition 53 azathioprine 53 antiretroviral naïve 53 Flurizan 53 biologic therapy 53 interferon IFN 53 glucose lowering 53 epithelial ovarian cancer 53 VEGF 53 DHFR 53 DLBCL 53 prostate adenocarcinoma 53 IV bisphosphonates 53 FTY# 53 nucleoside analogue 53 serum HCV RNA 53 resistant ovarian cancer 53 tipranavir 53 motavizumab 53 glomerular filtration rate 53 celecoxib 53 achieve sustained virologic 53 bisphosphonate therapy 53 cintredekin besudotox 53 chemo radiotherapy 53 rhTSH 53 CCR3 53 EDSS scores 53 choroidal neovascularization 53 dosage regimens 53 coinfected 53 elevated IOP 53 elacytarabine 53 hormone refractory prostate cancer 53 COPD 53 engraftment 53 Free Survival PFS 53 hormone deprivation 53 thrombotic complications 53 systemically administered 53 imatinib Gleevec ® 53 standard chemotherapy regimen 53 histologic 53 CDK inhibitor 53 systolic hypertension 53 metastatic colorectal cancer 53 neovascular 53 Scale EDSS 53 apoptotic 53 Kinoid 53 tamsulosin 53 coinfected patients 53 pioglitazone 53 follicular lymphoma 53 SCr 53 anemia hemoglobin 53 NATRECOR R 53 Tavocept 53 hyperglycaemia 53 medullary thyroid cancer 53 taxane chemotherapy 53 receptor inhibitor 53 HbA1c 53 idiopathic pulmonary fibrosis IPF 53 stratify patients 53 allogeneic transplantation 53 mepolizumab 53 panitumumab 53 endometrial carcinoma 53 colorectal neoplasia 53 severe oral mucositis 53 CTEPH 53 Aß 53 nonmetastatic 53 gastric emptying 53 ELND# 53 myelofibrosis 53 recurrent genital herpes 53 fluoropyrimidine 53 Raf MEK ERK 53 upper gastrointestinal bleeding 53 eplerenone 53 leukemic cell 53 pulmonary exacerbation 53 basal cell nevus syndrome 53 pramlintide 53 μmol L 53 chemoresistant 53 serum urate 53 aminotransferases 53 neurodegeneration 53 peg IFN 53 VAPRISOL 53 coadministration 53 HBeAg positive 53 p = #.# [002] 53 chemopreventive agent 53 cerebral ischemia 53 F FDG PET 53 neovascular AMD 53 breast carcinoma 53 BCG refractory 53 alemtuzumab 53 indolent NHL 53 cytotoxicity 53 transaminase levels 53 PSA nadir 53 chemotherapy regimens 53 antigen PSA levels 53 insulin resistance 53 diabetes mellitus DM 53 lipid lowering therapy 53 protease inhibitor PI 53 velafermin 53 cardiovascular calcification 53 ADAGIO study 53 NPM1 53 glomerular filtration 53 relapsing multiple sclerosis 53 leukemic cells 53 lipoatrophy 53 infliximab therapy 53 microglial activation 53 dose escalation 53 HBV DNA 53 HBeAg 53 kidney dysfunction 53 atherosclerotic progression 53 Rasagiline 53 leflunomide 53 dacarbazine 53 tumor necrosis 53 L dopa 53 antibody mediated 53 predictive biomarkers 53 urine NGAL 53 anti angiogenic therapy 53 forodesine 53 bronchodilation 53 paclitaxel Taxol 53 CTGF 53 pentoxifylline 53 flutamide 53 TRAIL induced apoptosis 53 HDAC inhibitors 53 alpha blocker 53 intravenous dosing 53 ZOLINZA 53 acute leukemias 53 lapatinib 53 neurodevelopmental outcome 53 denufosol 53 Eliezer Zomer Ph.D. 53 PXD# 53 AVODART 53 cetuximab Erbitux R 53 BCR ABL 53 Gleevec resistant 53 Betaferon ® 53 prognostic significance 53 bladder carcinoma 53 canakinumab 53 plus MTX 53 esophageal adenocarcinoma 53 enzastaurin 53 histopathologic diagnosis 53 response pCR 53 inotropic 53 immunological responses 53 5 FU 53 octreotide 53 hematologic toxicity 53 NF1 53 ritonavir boosted 53 pro apoptotic 53 postoperative mortality 53 dopaminergic therapy 53 HER2 expression 53 arterial calcification 53 endostatin 53 EGFR tyrosine kinase inhibitors 53 refractory NSCLC 53 T#I [002] 53 odanacatib 53 glioblastoma tumors 53 metabolic abnormalities 53 E selectin 53 perioperative morbidity 53 nonalcoholic steatohepatitis NASH 53 HBeAg seroconversion 53 metastatic renal cell 53 miR #a [001] 53 Thal Dex 53 β amyloid 53 spontaneous preterm birth 53 sJIA 53 recurrent atrial fibrillation 53 myelodysplastic syndromes MDS 53 CRp 53 HbA 1c levels 53 selective modulator 53 stage IIIB IV 53 prognostic variables 53 alkaline phosphatase ALP 53 symptomatic intracranial hemorrhage 53 renal insufficiency 53 recurrent stroke 53 chemoradiation 53 ACZ# 53 Alzheimer Disease AD 53 antiandrogen 53 MELD scores 53 prognostic marker 53 valsartan 53 BARACLUDE ® 53 SGS# 53 allopurinol 53 carcinoid 53 anterior uveitis 53 concomitant medications 53 thrombocytopenic 53 Fludara 53 serum cholesterol 53 Cloretazine 53 cytotoxic chemotherapy 53 hepatitis C genotype 53 EpCAM expression 53 QT intervals 53 Myelodysplastic Syndrome 53 knee osteoarthritis OA 53 aneurysmal subarachnoid hemorrhage 53 PEGPH# 53 lumiliximab 53 GSTP1 53 mRNA expression 53 YONDELIS 53 BPH symptoms 53 APOPTONE 53 cancer mCRC 53 tolvaptan 53 IV tPA 53 dexamethasone 53 otelixizumab 53 CANCIDAS 53 NGAL 53 ventricular arrhythmias 53 neutralizing antibody 53 apoB 53 chemoresistance 53 hypoglycemic episodes